Phase I/II Study of Cetuximab in Combination With Cisplatin or Carboplatin and Fluorouracil in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Bourhis, Jean; Rivera, Fernando; Mesı́a, Ricard; Awada, Ahmad; Geoffrois, L.; Borel, Christian; Humblet, Yves; Pousa, Antonio López; Hitt, Ricardo; Villegas, M. Eugenia Vega; Duck, Lionel; Rosine, Dominique; Amellal, Nadia; Schueler, Armin; Harstrick, A.

doi:10.1200/jco.2005.04.3547

Cited by 151 publications

(87 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17 The phase I study showed that the addition of cetuximab to a platinum/5-FU combination in the treatment of patients with recurrent and/or metastatic SCCHN was active and well tolerated in the first-line settings. 18 Cetuximab was also effective in nasopharyngeal carcinoma: the combination of cetuximab plus carboplatin showed an important clinical benefit in the patients with recurrent and/or metastatic nasopharyngeal carcinoma failing chemotherapy with an overall response rate of 12% and median overall survival of 7.6 months. 19 …”

Section: Squamous Cell Carcinoma Of the Head And Neck (Scchn)mentioning

confidence: 99%

Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème

Ocvirk¹,

Reberšek²

2008

Radiology and Oncology

View full text Add to dashboard Cite

show abstract

Section: Squamous Cell Carcinoma Of the Head And Neck (Scchn)mentioning

confidence: 99%

Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème

Ocvirk¹,

Reberšek²

2008

Radiology and Oncology

View full text Add to dashboard Cite

show abstract

“…24,25 When initial platinum-based therapy has failed, encouraging results have been reported in patients with recurrent and/or metastatic SCCHN for cetuximab both as monotherapy 26,27 and in combination with either cisplatin or carboplatin. [28][29][30][31] The objective of the analysis reported here was to determine more precisely the scope of cetuximab activity in recurrent and/or metastatic SCCHN in patients who progressed on platinum-based therapy by comparing the intention-to-treat efficacy data from 3 Phase II cetuximab studies with a retrospective study of a similar group of patients who were receiving various types of treatment outside an investigational setting.…”

mentioning

confidence: 99%

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies

Vermorken

Herbst

León

et al. 2008

Cancer

Self Cite

190

118

View full text Add to dashboard Cite

A novel aryl‐bridged triphenylamine derivative, 7‐t‐butyl‐5,5,9,9‐tetraaryl‐13b‐aza‐naphtho[3,2,1‐de]anthracene (ABTPA) was designed and synthesized. The alternating copolymers of ABTPA/dihexylfluorene (P1) and triphenylamine (TPA)/dihexylfluorene (P2) were synthesized by Suzuki coupling reaction. P1 shows excellent thermal stability with a decomposition temperature of 440 °C and a glass‐transition temperature of 326 °C. The HOMO energy levels of the two polymers are very close (−5.15 eV for P1 and −5.13 eV for P2). The maximum absorption peak of P1 is red shifted by 23 nm with respect to P2, because the incorporation of ABTPA units into the PF backbone enhances the electronic conjugation degree compared with the case of TPA units. The rigidity and the steric hindrance of the ABTPA in P1 result in a small Stokes shift and almost the same emission spectra of P1 between its film and solution. A PLED with simple configurations of ITO/P1/TNS (tetranaphthalen‐2‐yl‐silane)/Alq3 (tris(8‐hydroxyquinolinolato)aluminum)/Al emits a blue light with emission peak at 436 nm, and exhibits a maximum current efficiency of 1.89 cd/A and a maximum luminance of 4183 cd/m2, which is superior to the device with P2 as emissive layer under the identical conditions. These results indicate that ABTPA unit could be a very promising candidate to replace TPA unit and find widely application in organic/polymeric optoelectronic materials. © 2009 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 47: 3651–3661, 2009

show abstract

“…Three studies were excluded from the analysis: one study used an egfri in both arms 13 , one did not present rash rates according to either grades 3 and 4 criteria or allgrades criteria 14 , and one study was a duplicate of another study 15 . Thus thirteen studies were eligible for inclusion in the meta-analysis ( Table ii).…”

Section: Resultsmentioning

confidence: 99%

“…Only one study provided a rate of discontinuation because of rash (4%) 26 ; others reported discontinuations related to egfri reactions-for example, infusion-related or general toxicity 13,17,23 . Consequently, a systemic review of discontinuation rates could not be conducted, and the pooled difference in rates of discontinuation because of rash a Defined as the presence of one or more incidents of rash or desquamation, dry skin, nail changes, or other skin toxicity of all grades according to the National Cancer Institute's Common Toxicity Criteria, version 2.0. b Defined as any event described as rash, rash pustular, rash erythematous, dermatitis acneiform, dermatitis exfoliative, rash papular, rash pruritic, rash generalized, rash macular, rash maculopapular, acne, dry skin, acne pustular, and skin desquamation.…”

Section: Discussionmentioning

confidence: 99%

Rash Rates with EGFR Inhibitors: Meta-Analysis

Mittmann

Seung

2011

Current Oncology

View full text Add to dashboard Cite

Introduction: Currently marketed epidermal growth factor receptor inhibitors (EGFRIS) have been associated with high rates of dermatologic toxicity. Methods: We formally reviewed the literature at MEDLINE and EMBASE. Additional searches were conducted using Internet search engines. Studies were eligible if they were randomized controlled clinical trials of egfris, specifically cetuximab and panitumumab, in which at least one arm consisted of a non-egfri treatment and rash safety data were reported. The random effects method was used to pool differences in incident rash rates. Results are summarized as differences in incident rash (EGFRIS therapy rate minus the non-EGFRIS therapy rate) with corresponding 95% confidence intervals (CIS) for all severity grades of rash and for grades 3 and 4 rash. Results: Sixteen studies met the initial inclusion criteria of randomized controlled trials comparing EGFRIS with non-EGFRIS therapy. Seven publications that provided information on all severity grades of rash were found to have an overall difference in incident rash rate of 0.74 (95% CI: 0.68 to 0.81; p < 0.01). Thirteen studies that reported the incidence of grades 3 and 4 rash showed an overall difference in the incident rash rate of 0.12 (95% CI: 0.09 to 0.14; p < 0.01) between EGFRIS and non-EGFRIS therapy. Sensitivity analyses showed that the results were generally robust, but sensitive to small samples. Conclusions: Results quantify the difference in rash rates between EGFRIS and non-EGFRIS therapy.

show abstract

Phase I/II Study of Cetuximab in Combination With Cisplatin or Carboplatin and Fluorouracil in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Abstract: The combination of cetuximab, cisplatin/carboplatin, and FU was reasonably well tolerated and active in recurrent/metastatic SCCHN, and merits additional investigation. An FU dose of 1,000 mg/m2/d in combination with cisplatin or carboplatin can be recommended for additional studies.

Cited by 151 publications

References 21 publications

Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème

Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies

Rash Rates with EGFR Inhibitors: Meta-Analysis

Contact Info

Product

Resources

About